Dubba and Koppula synthesized a new series of indole-isoxazole hybrids as EGFR inhibitors; all compounds were evaluated against two breast cancer cell lines, and among this series, two compounds, St.56 and St.57 (Table 11), showed remarkable inhibitory activities against EGFR [176]. This evidence concerns the gene EGFR and breast carcinoma.